Kualitas bukti 4.75/5
Skor tinjauan delapan dimensi terhadap rubrik kualitas . Setiap dimensi dinilai 1–5.
- D1 Dasar sumber
- 5/5
- D2 Otoritas sumber
- 5/5
- D3 Aritmetika
- 5/5
- D4 Ketidakpastian
- 4/5
- D5 Cakupan
- 5/5
- D6 Prosa
- 5/5
- D7 Kejujuran persepsi
- 4/5
- D8 Kelengkapan peringatan
- 5/5
● faktor Anda — klik risiko ini ▾ untuk menampilkan
- Faktor Anda
≈ Sama mungkinnya dengan
Dipersepsikan
Ensefalitis akibat caplak adalah bagian berbahaya dari pasangan penyakit-caplak, dan di Eropa Tengah dan Timur ia secara konsisten dikalahkan oleh bagian yang lain. Ketika orang di Polandia, negara-negara Baltik, atau Ceko khawatir tentang «kleszcze», ketakutan yang disebut hampir selalu adalah borreliosis Lyme — infeksi bakteri yang jauh lebih umum tetapi, jika diobati dini, jauh lebih kecil kemungkinannya menyebabkan kerusakan yang bertahan lama. TBE adalah virus, ia dapat meradang otak dan selaputnya (meningitis dan ensefalitis), tidak ada pengobatan antivirus, dan tidak seperti Lyme ia dapat dicegah dengan vaksin. Namun penyerapan vaksin di sebagian besar sabuk endemik di luar Austria tetap rendah, yang merupakan sinyal terjelas bahwa penyakit yang spesifik, parah, dan dapat dicegah ini kurang dibobot dibandingkan dengan kecemasan musiman yang menyebar tentang caplak secara umum.
Perkiraan kasar: biasanya digabung ke dalam ketakutan umum terhadap caplak/Lyme; risiko TBE yang spesifik jarang dibedakan, dan vaksinnya tersedia luas tetapi kurang dimanfaatkan di luar Austria
Sumber: intuisi redaksi, bukan hasil survei
Aktual
~10 dari 100.000 per tahun (orang dewasa tidak divaksinasi, wilayah Eropa Tengah/Timur endemik tinggi)
orang dewasa tidak divaksinasi yang tinggal di fokus endemik tinggi Eropa Tengah/Timur (negara-negara Baltik, Ceko, Slovenia, Polandia timur laut)
Tampilkan perhitungan
Insiden TBE sangat fokal. Tingkat notifikasi rata-rata UE/EEA adalah 0,81 per 100.000 pada 2022 (ECDC), tetapi risiko terkonsentrasi di sabuk endemik tinggi di mana tingkatnya satu tingkat magnitudo lebih tinggi: Lituania melaporkan 13,4 per 100.000 dan Estonia 10,5 pada 2022, dan Ceko, Estonia, serta Lituania masing-masing telah melampaui 5 per 100.000 selama lima tahun berturut-turut. Polandia timur laut (Podlaskie) adalah fokus yang sama intensnya. Estimasi native sentral sebesar ~10 per 100.000 per tahun digunakan untuk orang dewasa tidak divaksinasi yang tinggal di sabuk endemik tinggi ini. Konversi seumur hidup selama horizon dewasa standar 59 tahun: 1 − (1 − 1,0 × 10⁻⁴)^59 ≈ 0,0059, dibulatkan menjadi 0,006 (sekitar 1 dari 170). Batas ketidakpastian bawah (0,003) mencerminkan fokus endemisitas lebih rendah atau paparan luar ruangan terbatas (~4–5 per 100.000); batas atas (0,012) mencerminkan tingkat nasional tertinggi yang dikombinasikan dengan paparan luar ruangan yang berat (~20 per 100.000). Angka ini menghitung TBE simtomatik yang didiagnosis secara klinis; kira-kira tiga perempat infeksi virus TBE tidak bergejala (CDC), sehingga tingkat infeksi beberapa kali lipat lebih tinggi daripada tingkat penyakit yang dinyatakan di sini. Cakupannya adalah subgroup_lifetime (penduduk Eropa endemik tinggi); untuk orang dewasa AS, risiko TBE yang didapat secara lokal secara efektif nol — hanya 12 kasus yang pernah dilaporkan di antara para pelancong AS.
Catatan: Angka 1-dari-170 adalah probabilitas seumur hidup TBE simtomatik yang didiagnosi…
Angka 1-dari-170 adalah probabilitas seumur hidup TBE simtomatik yang didiagnosis secara klinis untuk orang dewasa tidak divaksinasi yang tinggal di fokus endemik tinggi Eropa Tengah atau Timur; ini bukan angka penduduk AS dan bukan angka seluruh Eropa. Kira-kira tiga perempat infeksi virus TBE tidak bergejala, sehingga tingkat infeksi beberapa kali lebih tinggi daripada tingkat penyakit yang dinyatakan di sini, sementara tingkat penyakit neuroinvasif parah lebih rendah. Dua fakta membuat TBE berperilaku berbeda dari borreliosis Lyme, yang dengannya ia biasanya dikacaukan. Pertama, virus berada di kelenjar ludah caplak dan dapat menular dalam hitungan menit setelah menempel, sehingga pelepasan caplak yang cepat — sangat protektif terhadap Lyme, yang memerlukan 36+ jam penempelan — sedikit berpengaruh terhadap TBE; vaksinasi adalah penanggulangan utama. Kedua, TBE memiliki jalur pencernaan yang tidak dimiliki Lyme: minum susu tidak dipasteurisasi atau makan keju segar dari kambing, domba, atau sapi yang terinfeksi telah menyebabkan wabah keluarga dan desa yang terdokumentasi. Keparahan meningkat seiring usia. Untuk subtipe Eropa tingkat kematian kasus biasanya di bawah 2 %, tetapi gejala sisa yang bertahan lama dilaporkan pada 20–40 % kasus simtomatik dan defisit neurologis yang menetap hingga 10 %; namun sebagian besar pasien pulih sepenuhnya. Subtipe Timur Jauh yang beredar di Rusia dan sebagian Asia jauh lebih parah (kematian kasus hingga 20–40 %) dan berada di luar pembingkaian Eropa yang digunakan di sini. Entri ini bukan merupakan nasihat medis.
Bagaimana risiko bervariasi
Angka utama merata-ratakan situasi yang sangat berbeda. Berikut bagaimana probabilitas bervariasi berdasarkan skenario atau konteks:
1 dari 7.692
ECDC 2022: Lithuania 13.4 and Estonia 10.5 per 100,000 — the highest reported national notification rates in the EU/EEA. Lithuania reached 24–25 per 100,000 in 2019–2020.
1 dari 14.286
ECDC 2022: Czechia 6.7 and Slovenia 5.9 per 100,000; Latvia averaged 8.5 per 100,000 over 2018–2021 (did not report 2022). Local foci run higher than these national averages.
1 dari 100.000
ECDC 2022: 367 cases, national rate 1.0 per 100,000. Risk concentrates sharply in northeastern foci (Podlaskie), where a single Białystok hospital captures ~50% of the region's cases — well above the national average.
1 dari 123.457
ECDC 2022 average notification rate 0.81 per 100,000 — an order of magnitude below the high-endemic belt because risk is sharply focal.
1 dari 3.333.333.333
Effectively zero. Only 12 TBE cases have ever been reported among US travelers (1 in 1979, 11 during 2001–2021); there is no established local transmission.
Panjang dan gradasi warna batang memeringkat skenario ini satu sama lain, bukan terhadap risiko lain. Peluang pastinya ditampilkan di samping masing-masing.
Risiko terkait
Risiko lain dengan tema serupa — untuk menjelajahi ketakutan terkait.
Obat palsu
Berapa peluang dirugikan atau meninggal karena obat palsu atau berkualitas rendah?
Pilih penantang
Tick-borne encephalitis is the virus that the word “kleszcz” should evoke at least as readily as Lyme disease, and across most of its range it does not. For an unvaccinated adult living in a high-endemic Central or Eastern European focus — the Baltic states, Czechia, Slovenia, northeastern Poland — the lifetime probability of developing symptomatic TBE is roughly 1 in 170. The disease announces itself first as a flu-like phase, often followed after a brief remission by a second phase in which the virus inflames the lining of the brain and the brain itself: meningitis, encephalitis, or both. There is no antiviral treatment. Incidence is sharply focal — the EU/EEA average notification rate was 0.81 per 100,000 in 2022, but Lithuania reported 13.4 and Estonia 10.5, more than ten times the continental average — which is why a single figure for “Europe” badly misleads in both directions.
The perception gap is not the usual one of simple overestimation. People in the endemic belt are intensely tick-aware, but the awareness attaches almost entirely to Lyme borreliosis, the common bacterial infection that is usually treatable with antibiotics. TBE — rarer, untreatable once it reaches the brain, and the only one of the two with a vaccine — is the part of the risk that gets underweighted. The clearest evidence is behavioral: the TBE vaccine is roughly 91–99% effective after a full course, it is widely available across the endemic region, and yet outside Austria, where decades of public campaigns pushed coverage above 80% and cut cases dramatically, uptake remains low. The surveillance data make the gap concrete: of the EU/EEA cases in 2022 with known vaccination status, 94% were in people who had not been vaccinated. A cheap, highly effective countermeasure against a brain infection going largely unused is the signature of a fear pointed at the wrong target.
Two features set TBE apart from the Lyme risk it is confused with, and both cut against intuition. The protective habit that works for Lyme — checking for ticks and removing them quickly, since the Lyme bacterium needs a day and a half of attachment to transmit — does almost nothing for TBE, because the virus sits in the tick’s saliva and can pass within minutes of the bite. And TBE can be caught without any tick at all: unpasteurized milk and fresh cheese from infected goats, sheep, or cows have produced documented cluster outbreaks, a route borreliosis has no equivalent for. About three-quarters of infections cause no symptoms, and most people who do fall ill recover fully, but lasting sequelae follow 20–40% of symptomatic European-subtype cases and persistent neurological deficits up to 10%. For a US resident the number is a curiosity — only twelve cases have ever been recorded in American travelers — but for a forester in Podlaskie or a hiker in the Baltic woods, the vaccine is the variable that moves the odds most.
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
2/4 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
-
[1] US Centers for Disease Control and Prevention (MMWR Recommendations and Reports) — Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023 Terverifikasi
Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023- Statistik
Approximately three-fourths of TBE virus infections are asymptomatic; European-subtype case-fatality is usually <2%; sequelae occur in 20%–40% of European-subtype cases; vaccine effectiveness after ≥3 doses is 91%–99%, with 99% seroconversion after dose 3.- Kutipan
“"Approximately three fourths of TBE virus infections are asymptomatic. … Among patients with neurologic disease and infected with the European subtype virus, the case fatality rate is usually <2%. … Among patients infected with the European subtype virus, sequelae have been reported in 20%–40% overall, including neurologic sequelae (e.g., limb paresis or paralysis) in up to 10%. … VE estimates for the European subtype virus TBE vaccines against disease caused by the European subtype virus after ≥3 doses of vaccine are 91%–99%. … Among 416 adults seronegative at baseline, 411 (99%) were seropositive at 21–28 days after dose 3." ”
- Data sumber dari
- 2023-11-02
- Diakses
- 2026-06-21 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- Supplies the severity profile (CFR <2%, sequelae 20–40%, asymptomatic fraction ~75%) and the vaccine-efficacy basis for the personal factor multipliers. VE of 91–99% after the full primary series implies a residual risk multiplier of ~0.05× for a fully vaccinated person. The 12-US-traveler figure (1 case in 1979, 11 during 2001–2021) anchors the "effectively zero for US residents" framing.
- Independensi
- US CDC/ACIP synthesis of vaccine-trial and European-effectiveness data; independent of the ECDC surveillance counts used for incidence.
-
[2] European Centre for Disease Prevention and Control (ECDC) — Tick-borne encephalitis — Annual Epidemiological Report for 2022 Terverifikasi
Tick-borne encephalitis — Annual Epidemiological Report for 2022- Statistik
20 EU/EEA countries reported 3,650 TBE cases for 2022 (3,516 confirmed); EU/EEA notification rate 0.81 per 100,000, highest in Lithuania (13.4) and Estonia (10.5); 94.0% of cases with known vaccination status were unvaccinated. Poland reported 367 cases (rate 1.0).- Kutipan
“"For 2022, 20 EU/EEA countries reported 3 650 cases of tick-borne encephalitis (TBE), 3 516 (96.3%) of which were confirmed. … The EU/EEA notification rate for 2022 was 0.81 per 100 000 population. … The notification rate was highest in Lithuania (13.4 cases per 100 000 population), followed by Estonia (10.5). … Notification rates were consistently high (over five per 100 000 population) during the last five years in three countries: Lithuania, Estonia, and Czechia. … Of the 1 620 confirmed cases for which information about vaccination status was available, 1 522 (94.0%) were reported as not vaccinated against TBE." ”
- Data sumber dari
- 2024-06-01
- Diakses
- 2026-06-21 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- Provides the population-based incidence anchoring the native rate and the regional breakdown. The EU/EEA average of 0.81 per 100,000 versus the Baltic high-endemic rates of 10–13 per 100,000 (Lithuania historically to 24–25 in 2019–2020; Latvia averaging 8.5 over 2018–2021) establishes the ~10× focal concentration used in the assumptions. Poland's national rate was 1.0 per 100,000 (367 cases) in 2022, but risk concentrates in northeastern foci far above the national average. The 94%-unvaccinated figure among cases with known status anchors the underrated framing and the vaccine factor multiplier.
- Independensi
- European surveillance aggregation via EpiPulse/TESSy, independent of the US CDC synthesis and the single-centre Polish hospital series.
-
[3] Vaccines (Basel) — Sulik-Wakulińska, Toczyłowski & Grygorczuk — Breakthrough Tick-Borne Encephalitis and Epidemiological Trends in an Endemic Region in Poland: A Retrospective Hospital-Based Study, 1988–2020
Breakthrough Tick-Borne Encephalitis and Epidemiological Trends in an Endemic Region in Poland: A Retrospective Hospital-Based Study, 1988–2020- Statistik
1,518 patients were hospitalised for TBE at a single Białystok hospital over 1988–2020, capturing approximately 50% of all TBE cases reported in the (northeastern Poland) region.- Kutipan
“"Between 1988 and 2020, a total number of 1518 patients were hospitalized because of TBE [at the study hospital, which captures] approximately 50% of all TBE cases reported in the region. … Tick-borne encephalitis is endemic across much of Eurasia, [with] northeastern Poland [a] highly endemic area." ”
- Data sumber dari
- 2025-06-20
- Diakses
- 2026-06-21 · salinan arsip
- Perhitungan
- Confirms northeastern Poland (Podlaskie) as a high-endemic focus comparable to the Baltic belt, supporting its inclusion in the native population definition and the Polish regional_breakdown row. The single-centre series capturing ~50% of regional cases illustrates the focal clustering that the national-average rates obscure.
- Independensi
- Peer-reviewed single-centre Polish cohort, independent of both the ECDC aggregate counts and the US CDC recommendations.
-
[4] European Centre for Disease Prevention and Control (ECDC) — Country profile: Austria. Tick-borne encephalitis (TBE)
Country profile: Austria. Tick-borne encephalitis (TBE)- Statistik
Austria's TBE vaccination coverage is about 85% of the total population, following a sustained public campaign; annual cases have fallen to a range of 50-100 in the last decade, down from 300-700 per year before vaccination.- Kutipan
“"Today, vaccination coverage is at about 85% of the total population in Austria which – because of the effectiveness of the vaccine – has led to a dramatic decline in the disease in Austria, with the numbers of annual cases ranging from 50 to 100 in the last decade." ”
- Data sumber dari
- 2012-09-01
- Diakses
- 2026-07-04 · salinan arsip
- Perhitungan
- Supports the body-prose claim that Austria is the exception to the low regional vaccine uptake described elsewhere in this entry: a sustained public vaccination campaign pushed coverage to ~85% (above the ~80% threshold cited in the body) and cut annual case counts several-fold versus the pre-vaccination era (300-700/year down to 50-100/year). Independent of the EU/EEA-wide 2022 surveillance report and the CDC ACIP vaccine-efficacy synthesis already cited.
- Independensi
- ECDC country-specific surveillance profile for Austria, distinct from the EU/EEA-wide 2022 annual epidemiological report already cited in this entry.